Restatement of Previously Issued Unaudited Condensed Financial Statements for the Nine Months Ended November 30, 2021 (Details) - Schedule of the company’s previously issued balance	9 Months Ended
	Nov. 30, 2022 USD ($)
As Previously Reported [Member]
Condensed Financial Statements, Captions [Line Items]
Accrued expenses (including accrued interest)	$ 1,728,775
Note payable	385,353
Derivative warrant liability
Common stock	8,054
Additional paid-in capital	448,953,216
Accumulated deficit	(469,252,691)
Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Accrued expenses (including accrued interest)	(276,606)
Note payable
Derivative warrant liability	1,916,420
Common stock
Additional paid-in capital	(136,004)
Total liabilities	258,636
Share-based compensation addition	153,388
Accumulated deficit	(1,916,420)
Total stockholders’ deficit	136,004
Total liabilities and stockholders’ deficit	(258,636)
Share-based compensation expense	(153,388)
Payroll compensation expense	276,606
Reclassifications [Member]
Condensed Financial Statements, Captions [Line Items]
Accrued expenses (including accrued interest)	8,064
Note payable	(8,064)
Derivative warrant liability
Common stock	(2)
Additional paid-in capital	2
Total liabilities
Accumulated deficit
Total stockholders’ deficit
Total liabilities and stockholders’ deficit
Share-based compensation expense
Payroll compensation expense
As Restated [Member]
Condensed Financial Statements, Captions [Line Items]
Accrued expenses (including accrued interest)	1,460,233
Note payable	377,289
Derivative warrant liability	1,916,420
Common stock	8,052
Additional paid-in capital	449,229,238
Accumulated deficit	$ (471,168,525)